此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome (EMSIACS)

2020年11月20日 更新者:Yin Liu,MD、Tianjin Chest Hospital
The study is an open-label, multicenter, and randomized study(five hospitals).The purpose of this study is to assess the differences in the effects of the evolocumab added to moderate-intensity statin therapy and the moderate-intensity statin only therapy on the regulation of LDL-C levels in patients with acute phase acute coronary syndrome after four weeks of treatment. The primary outcome is the percentage change in LDL-C in weeks 4 and week 12 after treatment. The secondary outcome is the occurrence of MACE after 12 weeks and 1 year of treatment.

研究概览

研究类型

介入性

注册 (预期的)

500

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Tianjin、中国、300222
        • 招聘中
        • Tianjin Chest Hospital,
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Recent hospitalization for acute coronary syndrome: Complies with the diagnostic criteria for acute coronary syndrome (non-ST-segment elevation myocardial infarction, acute ST-segment elevation myocardial infarction, and unstable angina within 72 hours of onset)
  • LDL-C level (meet one of the following conditions):

    1. Prior to the study, patients who received intensive statins for more than 4 weeks (the same dose of statin therapy has been sustained for the past four weeks) with LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg /dL (≥2.6mmol/L) are included in the study;
    2. Prior to the study, patients who received moderate-intensity statin therapy for more than 4 weeks (the same dose of statin therapy has been sustained for the past four weeks) with LDL-C levels ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C≥ 120mg/dL (≥3.1mmol/L) are included in the study;
    3. Prior to the study, patients who do not receive statin therapy or who do not continue to receive statin with LDL-C ≥ 125 mg/dL (≥ 3.2 mmol/L) or non-HDL-C ≥ 155 mg/dL (≥ 4.0 mmol/L).
  • Being able to understand research requirements and sign informed consent

Exclusion Criteria:

  • Unstable clinical status (hemodynamics or ECG instability)
  • Uncontrolled arrhythmia, defined as recurrent or symptomatic ventricular tachycardia and atrial fibrillation with rapid ventricular reaction that the drug cannot control within three months prior to screening
  • Severe renal insufficiency, defined as estimated glomerular filtration rate<30ml/min/1.73m2
  • Active liver disease or liver dysfunction, whether it is on the patient's medical record or defined as an increase in alanine aminotransferase or aspartate aminotransferase more than 3 times above the upper limit of normal
  • Records on statin or rosuvastatin (any dose) intolerance or other statin intolerance
  • Known allergies to contrast agents, heparin, aspirin, ticagrelor or clopidogrel
  • Known allergies to the supplements required for the use of the drug
  • Patients who have been treated with evolocumab or other PCSK9 inhibitors
  • Received cholesterol ester transfer protein inhibitors treatment 12 months prior to screening
  • Received systemic steroid or cyclosporine treatment in the past 3 months
  • Known infections, hemorrhages, metabolic or endocrine disorders as determined by the researchers
  • Patients who have been included in other studies
  • Patients with active malignant tumor in need of treatment
  • Women with fertility (age <50 years, menstruation in the past 12 months), did not receive tubal ligation, oophorectomy or hysterectomy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:the evolocumab plus statin therapy
Patients with ACS are treated with atorvastatin (20mg) daily and evolocumab (140 mg) every two weeks throughout the study period
使用计算机生成的随机数将患者按 1:1 的比例随机分配,并分为两个治疗组:他汀类药物单独治疗和 evolocumab 联合他汀类药物治疗。
无干预:the statin alone therapy
Patients with ACS are treated with atorvastatin (20mg) daily throughout the study period.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Percent change in LDL-C
大体时间:4 weeks
4 weeks

次要结果测量

结果测量
措施说明
大体时间
Major cardiovascular adverse events
大体时间:4 weeks and 1 year
Coronary heart disease death,nonfatal myocardial infarction,hospitalization for unstable angina,unplanned coronary revascularization, and stroke
4 weeks and 1 year

其他结果措施

结果测量
措施说明
大体时间
The mean percentage change from baseline in LDL-C levels
大体时间:within 1 year
within 1 year
The proportion of patients with LDL-C <70 mg/dL during treatment
大体时间:week 4 and week 12
week 4 and week 12
the quality of life of patients
大体时间:week 12 and week 48
using EQ-5D-3L questionnaire score to assess the quality of life
week 12 and week 48
The effect of evolocumab on platelet function based on the area under curve
大体时间:from baseline to 72 hours and baseline to week 4
using Col/ADP test to evaluate platelet function
from baseline to 72 hours and baseline to week 4
the effect of evolocumab on the percentage change of inflammatory markers (high-sensitivity C-reactive protein)
大体时间:from baseline to week 48
from baseline to week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年1月1日

初级完成 (预期的)

2022年6月1日

研究完成 (预期的)

2023年6月1日

研究注册日期

首次提交

2019年9月21日

首先提交符合 QC 标准的

2019年9月21日

首次发布 (实际的)

2019年9月24日

研究记录更新

最后更新发布 (实际的)

2020年11月24日

上次提交的符合 QC 标准的更新

2020年11月20日

最后验证

2020年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅